Welcome to our dedicated page for Hcw Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HCW Biologics Inc. (NASDAQ: HCWB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a clinical-stage biopharmaceutical company developing fusion protein immunotherapies for inflammation-driven and age-related diseases, HCW Biologics uses its SEC filings to report on clinical progress, licensing transactions, financing activities, and Nasdaq listing status.
Investors can review Form 10-K and Form 10-Q filings for detailed discussions of the company’s TOBI and TRBC platforms, pipeline candidates such as HCW9302, HCW11-040, HCW11-018b, and HCW11-006, risk factors, and management’s analysis of operations and liquidity. Form 8-K current reports highlight material events, including warrant inducement agreements that generated gross proceeds from the exercise of existing warrants, securities purchase agreements, licensing and co-development arrangements with partners like Beijing Trimmune Biotech Co., Ltd., and notices from Nasdaq regarding compliance with Listing Rule 5550(b)(1) for continued listing.
Users can also track NT 10-Q notifications of late filings, which explain delays in quarterly reports, and amended 8-K filings that correct or update prior disclosures. Where applicable, Form 4 insider transaction reports can be reviewed to see equity dealings by officers, directors, or significant shareholders, providing additional context on insider activity.
Stock Titan’s AI tools summarize lengthy filings, highlight key terms such as going concern discussions, equity financing plans, and license fee structures, and surface references to clinical milestones like the initiation and design of the Phase 1 trial for HCW9302. Real-time updates from EDGAR ensure that new HCWB filings appear promptly, while AI-generated overviews help users quickly understand how each document relates to the company’s pipeline, partnerships, capital structure, and Nasdaq listing obligations.
HCW Biologics Inc. reported that its April 27, 2026 Special Meeting of Stockholders was adjourned without any business because there was no quorum. The two proposals scheduled for that meeting will instead be voted on at the virtual Annual Meeting on June 15, 2026, with an April 22, 2026 record date.
The company is asking stockholders to approve warrants issued to Armistice Capital Master Fund Ltd. to purchase up to 5,497,702 shares of common stock at $0.6055 per share. Armistice has invested $17.4 million in HCW Biologics. The company is required to seek stockholder approval every 60 days until it is obtained, which means it will continue to incur costs for additional voting efforts.
HCW Biologics Inc. plans to enter two consulting agreements that will begin only if a planned public offering on Form S-1 closes. The company expects both agreements to start on or about May 1, 2026 after the financing close.
HCW Biologics agreed to engage I.R. Agency LLC as a marketing consultant for future marketing efforts, with fees of $2.5 million to be paid from the public offering proceeds. It also agreed to engage Bowery Consulting Group as a financial consultant for six months, with a $500,000 fee, also payable from the same offering proceeds.
HCW Biologics Inc. is asking stockholders to approve several governance and capital structure actions at its June 15, 2026 virtual annual meeting. Key items include electing two Class II directors, ratifying Crowe LLP as auditor for 2026, and authorizing a reverse stock split between 1-for-5 and 1-for-20 to help maintain Nasdaq listing after a bid-price deficiency notice.
Stockholders are also asked to approve issuance of up to 2,477,292 shares upon exercise of Common Warrants and the repricing and share issuance upon exercise of 3,020,410 Existing Warrants at an adjusted exercise price of $0.6055, both tied to prior financings with Armistice Capital and Nasdaq Listing Rule 5635(d). The bylaws quorum threshold has been reduced to 33 1/3% of voting power to facilitate holding meetings.
HCW Biologics Inc. is registering up to 13,625,304 shares of common stock, or the same number of pre-funded warrants plus 13,625,304 underlying shares, in a reasonable best efforts public offering targeting gross proceeds of about $5.6 million. The assumed price is $0.411 per share, matching the April 20, 2026 Nasdaq close. Shares outstanding would rise from 6,734,104 to 20,359,408 if only stock is sold, creating substantial dilution; management estimates new investors would see about $0.08 per-share dilution at the assumed price. Net proceeds of roughly $5.2 million are expected to fund clinical development of lead programs such as HCW9302, research and development, business development and general corporate purposes. The deal has no minimum, so the company may receive significantly less if fewer securities are sold. The company is currently working to address Nasdaq bid-price compliance through a May 5, 2026 hearing while remaining an emerging growth and smaller reporting company.
HCW Biologics Inc. is registering up to 13,625,304 shares of common stock, up to 13,625,304 pre-funded warrants, and 13,625,304 shares underlying those warrants in a primary offering for gross proceeds of about $5.6 million on a reasonable best efforts basis.
The assumed offering price is $0.411 per share, matching the April 20, 2026 Nasdaq close. Common shares outstanding are 6,734,104 and would rise to 20,359,408 if only stock (no pre-funded warrants) is sold. Existing holders face immediate dilution, and there is no minimum raise or escrow, so the company may collect far less than the maximum.
Pre-funded warrants are aimed at investors otherwise exceeding 4.99% or 9.99% ownership caps and carry a $0.0001 exercise price with no expiry. Net proceeds are expected to be about $5.2 million at the full size, to fund clinical and preclinical development, including HCW9302 trials, R&D, marketing and general corporate uses. The company has recent Nasdaq bid-price and equity compliance history and a May 5, 2026 hearing regarding minimum bid price.
HCW Biologics Inc. is soliciting proxies for its 2026 virtual Annual Meeting on June 15, 2026 to elect Class II directors, ratify Crowe LLP as auditor, and seek shareholder approval for three corporate actions: a Board-authorized reverse stock split (range 1-for-5 to 1-for-20) to help maintain Nasdaq listing; approval to permit issuance upon exercise of up to 2,477,292 Common Warrants issued in February 2026; and approval to reprice and permit issuance upon exercise of up to 3,020,410 Existing Warrants to an exercise price of $0.6055 (reduced from $2.41).
The Board fixed the record date as April 22, 2026. The Company states Armistice invested $17.4 million under the February 2026 financing and that Proposals Four and Five must be re-submitted every 60 days until approved. The Board recommends a vote FOR all proposals.
HCW Biologics Inc. is changing its corporate rules to make it easier to conduct shareholder meetings. On April 15, 2026, the board approved a Bylaw amendment that, effective April 28, 2026, lowers the quorum needed to do business at stockholder meetings.
Going forward, holders of 33 1/3% of the voting power, present in person or by proxy, will be enough to constitute a quorum. Previously, the Bylaws required a majority of the voting power of outstanding shares entitled to vote to be present for business to proceed.
HCW Biologics Inc. presents an in-depth business overview as a clinical-stage immunotherapy company focused on diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated dysplasia.
The company’s lead candidate HCW9302, an IL‑2 fusion protein, entered a Phase 1 trial in alopecia areata in November 2025, with two active U.S. sites and ongoing dose escalation to establish a recommended Phase 2 dose. Preclinical programs include the “Big BiTE” T‑cell engager HCW11‑018b for solid tumors and checkpoint fusion HCW11‑040 initially targeting bronchopulmonary dysplasia.
HCW highlights commercial‑ready reagents HCW9206 and HCW9201 for CAR‑T and NK cell manufacturing, extensive patent coverage for its TOBI and TRBC platforms, and out‑licensing deals with Wugen and Trimmune. As of March 25, 2026, common shares outstanding total 6,734,104, and non‑affiliate equity value was about $6.2 million as of June 30, 2025.